One Cup of Coffee a Day Keeps AF Away? Insights from the DECAF Trial
November 10, 2025
Brand Name :
evkeeza
Synonyms :
Evinacumab, evinacumab-dgnb
Class :
Monoclonal antibody, antihyperlipidemic agents
Dosage Forms & StrengthsÂ
Injection, solution:Â
345mg/2.3ml(150mg/ml)Â
1200mg/8ml(150mg/ml)Â
Administer 15mg/kg intravenous once a month
Dosage Forms & StrengthsÂ
Injection, solution:Â
345mg/2.3ml(150mg/ml)Â
1200mg/8ml(150mg/ml)Â
<12 years: Safety and efficacy not established
>12 years:15mg/kg intravenous once a month
Refer adult dosingÂ
may decrease the therapeutic effect of Fc Receptor-Binding agents
Frequency defined:Â Â
>10%Â
NasopharyngitisÂ
1-10%Â
Infusion-related reactionsÂ
RhinorrheaÂ
Pain in extremityÂ
Nasal congestionÂ
Anaphylactic shockÂ
Influenza-like illnessÂ
NauseaÂ
DizzinessÂ
AstheniaÂ
Upper respiratory tract infectionÂ
Abdominal painÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: evinacumabÂ
Pronounced: (E-vin-AK-ue-mab)Â
Why do we use evinacumab?Â
It is used to treat homozygous familial hypercholesterolemiaÂ